Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Type of study
Publication year range
1.
Gynecol Oncol ; 171: 95-105, 2023 04.
Article in English | MEDLINE | ID: mdl-36842409

ABSTRACT

Endometrial stromal tumors (EST) are uterine mesenchymal tumors, which histologically resemble endometrial stroma of the functioning endometrium. The majority of EST are malignant tumors classified as low-grade endometrial stromal sarcoma (LG-ESS), high-grade endometrial stromal sarcoma (HG-ESS), and undifferentiated uterine sarcoma (UUS). Overall, ESTs are rare malignancies, with an annual incidence of approximately 0.30 per 100'000 women, mainly affecting peri- or postmenopausal women. The most common genetic alteration identified in LG-ESS is the JAZF1-SUZ12 rearrangement, while t(10;17)(q23,p13) translocation and BCOR gene abnormalities characterize two major subtypes of HG-ESS. The absence of specific genetic abnormalities is the actual hallmark of UUS. Unlike HG-ESSs, LG-ESSs usually express estrogen and progesterone receptors. Total hysterectomy without morcellation and bilateral salpingo-oophorectomy (BSO) is the first-line treatment of early-stage LG-ESS. Ovarian preservation, fertility-sparing treatment, and adjuvant hormonal therapy ± radiotherapy may be an option in selected cases. In advanced or recurrent LG-ESS, surgical cytoreduction followed by hormonal treatment, or vice versa, are acceptable treatments. The standard treatment for apparently early-stage HG-ESS and UUS is total hysterectomy without morcellation with BSO. Ovarian preservation and adjuvant chemotherapy ± radiotherapy may be an option. In advanced or recurrent HG-ESS, surgical cytoreduction and neoadjuvant or adjuvant chemotherapy can be considered. Alternative treatments, including biological agents and immunotherapy, are under investigation. LG-ESSs are indolent tumor with a 5-year overall survival (OS) of 80-100% and present as stage I-II at diagnosis in two third of patients. HG-ESSs carry a poor prognosis, with a median OS ranging from 11 to 24 months, and 70% of patients are in stage III-IV at presentation. UUS median OS ranges from 12 to 23 months and, at diagnosis, 70% of patients are in stage III-IV. The aim of this review is to assess the clinical, pathological, and biological features and the therapeutic options for malignant ESTs.


Subject(s)
Endometrial Neoplasms , Endometrial Stromal Tumors , Sarcoma, Endometrial Stromal , Humans , Female , Endometrial Stromal Tumors/epidemiology , Endometrial Stromal Tumors/genetics , Endometrial Stromal Tumors/therapy , Sarcoma, Endometrial Stromal/epidemiology , Sarcoma, Endometrial Stromal/genetics , Sarcoma, Endometrial Stromal/therapy , Endometrial Neoplasms/epidemiology , Endometrial Neoplasms/genetics , Endometrial Neoplasms/therapy , Uterus/pathology , Endometrium/pathology
2.
Food Chem Toxicol ; 48(10): 2663-9, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20600527

ABSTRACT

The toxicity of sodium stearoyl lactylate (SSL) was examined in Wistar rats fed diets containing 0, 1.25, 2.5, and 5% SSL for one year, equivalent to mean daily intakes of 558, 1115, and 2214 mg/kg/day in males and 670, 1339, and 2641 mg/kg/day in females, respectively. SSL was well tolerated at these dietary levels as evidenced by the absence of toxicologically significant changes in the general condition and appearance of the rats, survival, neurobehavioral endpoints, growth, feed and water intake, ophthalmoscopic examinations, hematology and clinical chemistry parameters, urinalysis, or necropsy findings. The occurrence of uterine endometrial stromal polyps was the only finding of potential significance. Given the frequent occurrence of these benign tumors in rats, wide variability in the reported incidence of this type of polyps in rats, the lack of statistical significance and lack of biological evidence to suggest a mechanism for the slightly greater incidence in the groups fed 2.5 and 5% SSL, it was concluded that the endometrial stromal polyps observed in females fed SSL were not related to treatment. The no observed adverse effect level (NOAEL) of SSL was placed at 5%, the highest dietary level tested (equivalent to 2214 mg/kg/day for males and 2641 mg/kg/day for females).


Subject(s)
Stearates/toxicity , Animals , Body Weight/drug effects , Carcinogenicity Tests , Dose-Response Relationship, Drug , Drinking/drug effects , Eating/drug effects , Emulsions , Endometrial Stromal Tumors/epidemiology , Female , Leukocyte Count , Male , Neoplasms/epidemiology , No-Observed-Adverse-Effect Level , Rats , Rats, Inbred F344 , Sex Characteristics , Survival , Urinalysis
SELECTION OF CITATIONS
SEARCH DETAIL